Our Pricing

Prescription Weight Loss UK: Orlistat vs Ozempic

Published on: June 03, 2026

When comparing prescription weight loss UK orlistat vs ozempic options, understanding the fundamental differences between oral fat-blocking tablets and injectable GLP-1 medications helps you make an informed choice. At Cured Pharmacy, our UK-registered clinical team provides free consultations to assess which prescription treatment aligns with your medical history, lifestyle, and weight loss goals.

How Orlistat Works for Weight Loss

Orlistat is a lipase inhibitor that works in your digestive system by blocking approximately 30% of dietary fat from being absorbed [1]. Unlike appetite suppressants or metabolic treatments, orlistat acts locally in the gut without entering your bloodstream, making it suitable for patients who prefer non-systemic medications.

Clinical trials demonstrate that orlistat combined with a reduced-calorie diet can help patients achieve an average 5-10% body weight reduction over 12 months [1]. The medication is most effective when dietary fat intake is distributed evenly across three main meals, as this optimises the fat-blocking mechanism throughout the day.

Common side effects relate directly to its mechanism — unabsorbed fat passes through the digestive system, which may cause oily stools, increased bowel movements, and flatulence, particularly if you consume high-fat meals [1]. These effects typically diminish as patients adjust their dietary fat intake to recommended levels below 30% of total calories.

How Ozempic and Semaglutide Injections Work

Ozempic contains semaglutide, a GLP-1 receptor agonist originally licensed for type 2 diabetes management but increasingly prescribed off-label for weight management in the UK [2]. Semaglutide mimics a natural gut hormone that regulates appetite, slows gastric emptying, and influences blood sugar control through multiple pathways.

The STEP clinical trial programme demonstrated that semaglutide 2.4mg (marketed as Wegovy for weight management) produced an average 15% body weight reduction over 68 weeks — significantly higher than traditional oral medications [2]. Patients typically report reduced hunger, earlier satiety during meals, and decreased food cravings, making it easier to maintain a calorie deficit.

As a once-weekly subcutaneous injection, semaglutide offers convenience compared to daily medications. Common side effects include nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation phases [2]. These gastrointestinal effects usually improve within 4-8 weeks as your body adapts to the medication.

Wegovy vs Ozempic: Understanding the Difference

Both medications contain semaglutide, but Wegovy is specifically licensed by the MHRA for chronic weight management at higher doses (up to 2.4mg weekly), while Ozempic is licensed for type 2 diabetes at lower doses (up to 1mg weekly). Your UK prescriber will determine which formulation and dose is appropriate based on your clinical assessment and treatment goals.

Orlistat vs Ozempic: Key Differences Explained

The fundamental difference lies in their mechanisms: orlistat blocks fat absorption in your gut without affecting appetite or metabolism, while semaglutide-based treatments work systemically to reduce hunger and regulate blood sugar. This means orlistat requires active dietary management to avoid side effects, whereas GLP-1 medications naturally reduce appetite, making calorie restriction feel less restrictive.

Efficacy data shows distinct differences — clinical trials indicate orlistat typically produces 5-10% body weight reduction, while semaglutide injections can achieve 15-20% weight loss on average [1][2]. However, individual results vary significantly based on adherence, lifestyle modifications, and metabolic factors that your prescriber will assess during consultation.

Cost considerations differ substantially between these treatments. Administration method also influences patient preference — some prefer the simplicity of taking tablets with meals, while others find once-weekly injections more convenient than daily oral medication. Your UK prescriber at Cured Pharmacy will discuss these practical factors during your free clinical assessment.

Which Patients Suit Each Treatment?

Orlistat may be more suitable if you prefer non-systemic medications, have concerns about injectable treatments, or have a diet naturally higher in fat that you're willing to modify. GLP-1 medications like semaglutide may be recommended if you struggle with appetite control, have tried lifestyle modifications without sufficient success, or have concurrent metabolic conditions like prediabetes that benefit from GLP-1 therapy [2][3].

Clinical Effectiveness: What the Evidence Shows

A 2023 systematic review comparing weight loss medications found that GLP-1 receptor agonists consistently outperform lipase inhibitors in head-to-head efficacy studies, with semaglutide demonstrating superior weight reduction and metabolic improvements [3]. However, orlistat remains a valuable first-line option for patients who cannot tolerate or prefer to avoid injectable treatments.

Long-term adherence patterns differ between medication classes. Studies indicate that gastrointestinal side effects cause approximately 15-30% of orlistat users to discontinue treatment within the first six months, while GLP-1 medications show higher continuation rates once patients complete dose escalation [3]. Your prescriber will discuss realistic expectations and strategies to optimise adherence for whichever treatment you're prescribed.

Cardiovascular outcome data increasingly favours GLP-1 therapies — the SELECT trial demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease, benefits not observed with orlistat [4]. This makes semaglutide particularly valuable for patients with obesity and concurrent cardiovascular risk factors, subject to prescriber assessment.

Prescription Weight Loss UK: The Assessment Process

All prescription weight loss medications at Cured Pharmacy require clinical assessment by a UK-registered prescriber before dispensing. Our online consultation takes under three minutes and covers your medical history, current medications, previous weight loss attempts, and any contraindications that might affect treatment suitability.

Your prescriber evaluates multiple factors including your BMI, presence of weight-related comorbidities, previous response to weight loss treatments, and personal preferences regarding administration method. NICE guidelines recommend prescription weight loss medications for adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with weight-related conditions such as type 2 diabetes or hypertension [5].

After approval, your medication is dispensed from our UK-registered pharmacy (GPhC 9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073). We provide discreet packaging, clear dosing instructions, and ongoing support throughout your treatment journey. Prescription renewals require periodic clinical review to monitor progress and adjust treatment as needed.

What Happens After Your Consultation?

If your prescriber approves treatment, you'll receive confirmation within hours, and your medication is typically dispatched the same working day for next-day delivery across the UK. All pricing is transparent before consultation — you'll know the exact cost before starting your clinical assessment, with no hidden fees or surprise charges at checkout.

Getting Started with Prescription Weight Loss at Cured Pharmacy

Starting your prescription weight loss journey at Cured Pharmacy begins with our free online consultation, accessible 24/7 from any device. The streamlined assessment takes most patients under three minutes to complete, and our UK clinical team reviews submissions promptly, typically within a few hours during working days.

We stock genuine UK-licensed medications only, sourced through regulated pharmaceutical supply chains and stored in our GPhC-registered facility. Wegovy (semaglutide) weight loss injections start from £79.00, representing competitive UK pricing with transparent upfront costs shown before you begin your consultation.

Our service includes comprehensive patient information leaflets, injection technique guides for GLP-1 medications, dietary advice to optimise treatment outcomes, and access to our UK-based pharmacy team for any questions during treatment. Whether you're prescribed orlistat tablets or semaglutide injections, you'll receive the clinical support needed to maximise your weight loss success safely and effectively.

Scientific References

1. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Khera, R., Murad, M. H., Chandar, A. K., et al. (2016). Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA, 315(22), 2424–2434. https://doi.org/10.1001/jama.2016.7602 [accessed 13 August 2026]
4. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment and lifestyle modifications.